What were the main reasons for the financial restatement?

The financial restatement was primarily due to issues identified during an internal review by the Audit Committee, stemming from the SEC investigation and U.S. Attorney inquiry. Key areas included the classification of sales between 'Operating Revenue' and 'Bulk Deliveries to Customer Warehouses and Other,' the practice of accelerating cash discounts earned from suppliers, the timing of revenue recognition in the Automation and Information Services segment, and various errors or misapplications of GAAP related to balance sheet reserve and accrual adjustments.

What is the significance of the ALARIS acquisition?

The acquisition of ALARIS Medical Systems for approximately $2.1 billion (including debt assumption) was a major strategic move for Cardinal Health. It significantly expanded the company's portfolio in the high-growth area of intravenous medication safety products and services, positioning Cardinal Health to offer a more comprehensive suite of medication safety solutions.

What are the risks associated with the business model transition in Pharmaceutical Distribution?

The transition of the Pharmaceutical Distribution business model from compensation based on manufacturers' sales and pricing practices to a fee-for-service model presents significant risks. There is no assurance that the transition will be successful or timely. If it fails, Cardinal Health may not be adequately compensated for its services, potentially leading to a significant reduction in profitability. The company is working with manufacturers to establish new distribution services agreements with reliable and predictable compensation.

What is the company doing to address the identified material weaknesses in internal controls?

Cardinal Health is implementing several measures to address the identified material weaknesses in internal controls. These include appointing new finance leadership with relevant expertise, enhancing the internal audit function, establishing new governance processes for financial reporting, revising revenue recognition policies, implementing enhanced training programs, and performing rigorous audits of key processes. The company believes these enhancements will remediate the weaknesses for future periods.

CAH 10-K FY2004 Annual Report — Revenue, Net Income, EPS

Summary

Cardinal Health, Inc.'s 2004 10-K filing reveals a year marked by significant events, most notably an ongoing SEC investigation and a U.S. Attorney inquiry into the company's accounting practices. This led to a restatement of financial statements for fiscal years 2000 through 2003 and the first three quarters of fiscal 2004. The restatements stemmed from issues related to revenue classification, accelerated recognition of cash discounts, timing of revenue recognition in the Automation and Information Services segment, and various balance sheet reserve adjustments. Despite these accounting challenges, Cardinal Health continued to grow its revenue by 15% to $65.1 billion, driven by strong performance across its diversified business segments, including Pharmaceutical Distribution and Provider Services, Medical Products and Services, and Pharmaceutical Technologies and Services. The company also completed a major acquisition of ALARIS Medical Systems for approximately $2.1 billion, expanding its offerings in intravenous medication safety. The company is also navigating a critical transition in its Pharmaceutical Distribution business model, shifting towards a fee-for-service compensation structure with manufacturers, which presents both opportunities and uncertainties.

Key Highlights

1The company is subject to a formal SEC investigation and a U.S. Attorney inquiry concerning accounting practices, leading to a restatement of financial statements for fiscal years 2000-2003 and the first three quarters of fiscal 2004.
2Revenue increased by 15% to $65.1 billion, reflecting growth across most business segments.
3Cardinal Health acquired ALARIS Medical Systems for approximately $2.1 billion, significantly expanding its presence in medication safety products.
4The Pharmaceutical Distribution business is transitioning to a fee-for-service model with manufacturers, a process expected to be completed by April 1, 2005.
5Material weaknesses in internal controls were identified, primarily related to revenue recognition, reserve accounting, and disclosure processes, with remediation efforts underway.
6The company's largest customer, CVS, accounted for 18% of fiscal 2004 revenue, highlighting a significant customer concentration.
7Merger and restructuring costs, alongside litigation settlements, impacted reported earnings, though specific items are detailed as special items.

CARDINAL HEALTH INC Annual Report, Year Ended Jun 30, 2004

Summary

Key Highlights

Frequently Asked Questions